---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-002761"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:24:06.624260+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11

## Summary
- Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.
- Option has 10-year term, vests in three equal annual installments starting Jan 26, 2024, subject to continued service.
- Grant approved by Compensation Committee as inducement material to Dr. Guzman's employment as CMO and SVP of Medical Affairs.
- Inducement award was granted outside ZyVersa's 2022 Equity Incentive Plan under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001493152-23-002761
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/0001493152-23-002761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-002761
- JSON: https://secwatch.observer/filing/0001493152-23-002761.json
- Plain text: https://secwatch.observer/filing/0001493152-23-002761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.